ISP passes on ingredient price hikes to drugmakers

Better alert purchasing because drug ingredient prices are going up, up, up again. All of its biocide products--especially those containing 3-Iodo-Propynyl-Butylcarbamate--are subject to a 10 percent price hike in June, says International Specialty Products of Wayne, NJ. The cost increase comes on top of one made in March.

ISP cites raw material cost escalation, especially for iodine, along with increasing regulatory, compliance, energy and transportation costs as co-conspirators.

Separately, ISP announced a 10 percent across-the-board boost for polymer, vinyl monomer, emollient, emulsifier, preservative and encapsulates prices. This increase follows a 10 percent bump in February. Then as now, material and energy cost escalation is the culprit.

Just two weeks ago, contract manufacturer Lonza cited rising raw material prices as having an impact on its first-half financial performance.

- here's the biocides announcement
- see the polymers release
- see the Lonza story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.